Filtered Listing Testing
A small layer of tissue lying next to the retina, called the RPE, may serve as a tipping point in AMD. Read about BrightFocus-funded research on display at ARVO 2016.
BrightFocus Foundation today honored five scientists in the fields of macular degeneration and glaucoma research, awarding them grants named in honor of leaders in vision research and advocacy.
Noted vision researcher Dr. Dean Bok of UCLA is the recipient of the prestigious 2016 Helen Keller Prize for Vision Research. Dr. Bok is being honored for more than four decades of discoveries in the field of retinal cell biology.
The spring 2016 edition of Alzheimer's Disease Research Review addresses the consequences of brain injury on Alzheimer’s disease, and the potential protective benefits of statins (cholesterol-lowering medications) in improving brain recovery after a concussion. Also read about BrightFocus Foundation's support of the Dementia Friendly America Campaign, meet Makoto Ishii, MD, PhD, who is investigating the complex interactions between body weight and Alzheimer’s disease, and much more.
Why do immune sensors known as toll-like receptors (TLRs) become activated and contribute to the AMD disease process? Also read our profile of Doyle and her husband, BrightFocus grantee Matthew Campbell, PhD.
BrightFocus Foundation today announced $11.7 million in promising new scientific research projects, its largest annual investment toward finding cures for Alzheimer’s disease, macular degeneration, and glaucoma.
CentraSight® by VisionCare Ophthalmic Technologies, Inc., today announced a partnership with leading non-profit, BrightFocus Foundation to further patient research and education for advanced age-related macular degeneration (AMD) through a direct-to-patient outreach and survey program.